EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
With the addition of sodium-glucose cotransporter-2 inhibitors to the current arsenal of oral antidiabetics (OAD), a lot has changed. From questioning their glucouretic mechanism to understanding their pleiotropic effects, it has been an eventful journey. In 2008, after the rosiglitazone fiasco, the...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Wolters Kluwer Medknow Publications,
2017-01-01T00:00:00Z.
|
| Teme: | |
| Online pristup: | Connect to this object online. |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Budi prvi tko komentira!